Organization
Institut Curie
32 clinical trials
Clinical trial
Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic CounselingStatus: Recruiting, Estimated PCD: 2033-01-02
Clinical trial
A Phase I Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) With Dose Expansion Cohorts in Patients With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-06-15
Clinical trial
Analysis of Circulating Tumor Markers in the BloodStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 StudyStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
CombinaiR3 - First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 YearsStatus: Completed, Estimated PCD: 2022-08-01
Clinical trial
A Phase-I Study of Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NiCOLStatus: Completed, Estimated PCD: 2020-10-30
Clinical trial
A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual DiseaseStatus: Completed, Estimated PCD: 2020-02-17
Clinical trial
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System LymphomaStatus: Recruiting, Estimated PCD: 2024-01-15
Clinical trial
Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.Status: Recruiting, Estimated PCD: 2026-03-15
Clinical trial
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG CancerStatus: Recruiting, Estimated PCD: 2024-10-09
Clinical trial
Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT TracersStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II TrialStatus: Recruiting, Estimated PCD: 2026-08-15
Clinical trial
A Phase II, Monocentric, Single Arm Trial Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma PatientsStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase Ib/II Study on AsiDNA in Association With Re-irradiation in Children, Adolescents and Young Adults With High-grade GliomaStatus: Terminated, Estimated PCD: 2023-09-20
Clinical trial
A Double-blind Randomized Non-inferiority Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery: Effects on Acute Postoperative Pain.Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
A Double-blind Randomized Trial of Interpectoral Nerve Block (Pecs 1 and 2) With Ropivacaine Versus Placebo Before Breast Cancer Surgery: Effects on Acute Postoperative Pain. (MIRs 04)Status: Completed, Estimated PCD: 2021-12-30
Clinical trial
Milademetan and Fulvestrant in GATA3-mutant, ER-positive, HER2-negative Advanced or Metastatic Breast Cancer Patients: a Multicenter Phase II TrialStatus: Terminated, Estimated PCD: 2023-11-24
Clinical trial
Study to Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (R0)Status: Completed, Estimated PCD: 2020-02-25
Clinical trial
Use of Specific Genetic Alteration s of Tumoral Cells Identified by NGS to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor -Status: Completed, Estimated PCD: 2021-01-01
Clinical trial
3D Elastography (Shear Wave) : Assessment of Response to Neo-adjuvant Chemotherapy (NACT) : in Vivo Quantification, for Patients With a Locally Advanced Breast Cancer.Status: Completed, Estimated PCD: 2020-09-09
Clinical trial
Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018Status: Recruiting, Estimated PCD: 2035-01-20
Clinical trial
Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal MelanomaStatus: Completed, Estimated PCD: 2012-02-01
Clinical trial
Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye SyndromeStatus: Active (not recruiting), Estimated PCD: 2027-02-01
Clinical trial
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary EnucleatedStatus: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
Conservative Treatments of RetinoblastomaStatus: Active (not recruiting), Estimated PCD: 2023-01-01
Clinical trial
A Phase II Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-08-19
Clinical trial
Study of Circulating Tumoral DNA Evolution in Plasma in Choroidal MelanomaStatus: Completed, Estimated PCD: 2019-04-02
Clinical trial
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 TrialStatus: Completed, Estimated PCD: 2017-01-01
Clinical trial
Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase IIStatus: Recruiting, Estimated PCD: 2026-12-19
Clinical trial
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2028-08-15
Clinical trial
"neoBREASTIM": A Phase 2 Study of Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2026-04-05